QMMM Holdings Limited Announces to receive Nasdaq Minimum Bid Price Deficiency Letter February 28, 2025 β 23:00
Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT001, a Novel Multi-Targeting, Half-Life Extended Bispecific Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Skin Diseases February 28, 2025 β 22:58
Trip.com Group champions further recovery and long-term growth for ASEAN tourism January 27, 2025 β 15:43
Supermicro Begins Volume Shipments of Max-Performance Servers Optimized for AI, HPC, Virtualization, and Edge Workloads January 9, 2025 β 22:05
MANTRA and DAMAC Group Revolutionize Tokenized Real-World Assets with US$1 Billion Deal January 9, 2025 β 22:00
Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease November 8, 2024 β 17:45